Meeting Banner
Abstract #0093

ACRIN 6702 DWI Trial: The Value of Alternate ADC Metrics Compared to Standard ADC for Decreasing Breast MRI False-Positives

Habib Rahbar1, Zheng Zhang2, Justin Romanoff2, Lucy G Hanna2, Christopher E. Comstock3, and Savannah C Partridge1

1Radiology, University of Washington, Seattle, WA, United States, 2ACRIN Biostatistics Center, Brown University, Providence, RI, United States, 3Memorial Sloan Kettering Cancer Center, New York, NY, United States

The ACRIN 6702 trial confirmed that standard ADCs from multi b-value DWI acquisition are lower in malignancies than in benign lesions and that application of standard ADCs can eliminate one in five unnecessary biopsies. Secondary analysis from this trial demonstrated that application of alternate ADC metrics, including perfusion insensitive ADCØ and normalized ADC provide no practical benefit over standard ADC for improving conventional DCE-MRI performance. These findings suggest that standard ADC calculations alone are sufficient for improving breast MRI specificity and should be the primary metric included in the next edition of the BI-RADS atlas.

This abstract and the presentation materials are available to members only; a login is required.

Join Here